Actelion will host an investor conference call and webcast to discuss the MERIT results and provide an update on its cardiovascular pipeline at 14:00 hrs CET ALLSCHWIL/BASEL, SWITZERLAND - 07 November 2016 - Actelion Ltd (SIX: ATLN) today announced that the MERIT study to assess the efficacy, safety and tolerability of macitentan in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH; Pulmonary hypertension group 4) has met its primary endpoint. In MERIT, 80 inoperable CTEPH patients were randomized 1:1 to receive either macitentan 10 mg once daily or placebo. After 16 weeks the treatment effect was a significant 16% reduction in pulmonary vascular resistance (PVR)...
↧